Study identifies a potential therapeutic target for lung cancer

Small-cell lung cancer (SCLC) is one of the deadliest types of cancer, and it has been several decades since new treatment options have been approved for this disease. Although recent advances in cancer treatments have focused on promising therapies that trigger the immune system to attack cancer cells, no immunological approaches have been developed to treat SCLC.

In this month's issue of the JCI, a team led by Julian Sage and Irving Weissman at Stanford University identified a molecular target that may stimulate a patient's own immune system to destroy lung tumors. They determined that a protein called CD47 is highly expressed on the surface of SCLC cells. Although CD47 is also found in , its expression on can help hide tumors by inhibiting the immune system. In the study, a treatment that blocked CD47 enabled the immune system to target and destroy SCLC cells, which prevented tumor growth in a mouse model.

These findings suggest that CD47 may be an effective target for immunological therapies for SCLC, and supports the development of similar approaches for treating other types of cancer.


Explore further

Two-drug immunotherapy deemed safe for lung cancer patients, study shows

More information: Kipp Weiskopf et al, CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI81603
Provided by JCI Journals
Citation: Study identifies a potential therapeutic target for lung cancer (2016, June 13) retrieved 19 June 2019 from https://medicalxpress.com/news/2016-06-potential-therapeutic-lung-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more